3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
79
Breast Neoplasms
7
Neoplasms
6
Prostate Adenocarcinoma
2
Polycystic Ovary Syndrome
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leiomyoma
2
Hodgkin Disease
2
Uveal Melanoma
1
Urogenital Neoplasms
1
Sleep Apnea, Obstructive
1
Skin Neoplasms
1
Recurrence
1
Prostatic Diseases
1
Premenopausal Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
PSA Level Greater Than Two
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoplasms, Glandular and Epithelial
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Metabolic Syndrome
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphatic Metastasis
1
Lower Urinary Tract Symptoms
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
Alpelisib
4
berzosertib
3
Fulvestrant
3
Everolimus
3
parsaclisib
2
Topotecan
2
NVP-BKM120
2
Cetuximab
2
talazoparib
1
sotorasib
1
serabelisib
1
ruxolitinib
1
duvelisib
1
dapagliflozin
1
cobimetinib
1
ceralasertib
1
binimetinib
1
avelumab
1
Vemurafenib
1
SF 1126
1
Rituximab
1
Paclitaxel
1
Oxaliplatin
1
Leuprolide
1
Leucovorin
1
Letrozole
1
Irinotecan
1
Goserelin
1
Fluorouracil
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hereditary Sensory and Autonomic Neuropathies
×
Leuprolide
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts